Hantz Financial Services Inc. Has $4.86 Million Position in Stryker Co. (NYSE:SYK)

Hantz Financial Services Inc. cut its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 14.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,504 shares of the medical technology company's stock after selling 2,279 shares during the period. Hantz Financial Services Inc.'s holdings in Stryker were worth $4,862,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of SYK. Capital Planning LLC boosted its holdings in shares of Stryker by 3.6% in the fourth quarter. Capital Planning LLC now owns 841 shares of the medical technology company's stock valued at $304,000 after acquiring an additional 29 shares in the last quarter. Alhambra Investment Management LLC increased its stake in shares of Stryker by 1.5% during the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock worth $719,000 after purchasing an additional 29 shares in the last quarter. Avestar Capital LLC grew its stake in Stryker by 1.1% in the 3rd quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company's stock worth $1,065,000 after acquiring an additional 31 shares during the period. Union Savings Bank grew its holdings in Stryker by 1.0% in the 4th quarter. Union Savings Bank now owns 3,162 shares of the medical technology company's stock valued at $1,138,000 after buying an additional 31 shares during the period. Finally, Patrick M Sweeney & Associates Inc. increased its position in Stryker by 1.5% during the third quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company's stock worth $793,000 after purchasing an additional 32 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Price Performance

Shares of Stryker stock traded up $3.23 during midday trading on Thursday, hitting $394.30. 497,982 shares of the company were exchanged, compared to its average volume of 1,539,874. The firm has a 50 day simple moving average of $376.55 and a 200-day simple moving average of $362.18. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The firm has a market cap of $150.32 billion, a P/E ratio of 42.25, a PEG ratio of 2.68 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same period last year, the business posted $3.46 EPS. Research analysts forecast that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.84 per share. This is a boost from Stryker's previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. The ex-dividend date is Tuesday, December 31st. Stryker's dividend payout ratio is 36.01%.

Wall Street Analyst Weigh In

SYK has been the subject of several research analyst reports. Stifel Nicolaus upped their price target on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research note on Wednesday. Canaccord Genuity Group raised their price target on shares of Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research report on Wednesday. JPMorgan Chase & Co. raised their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a report on Wednesday. Barclays increased their price target on Stryker from $402.00 to $418.00 and gave the stock an "overweight" rating in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group raised their target price on Stryker from $384.00 to $427.00 and gave the company a "neutral" rating in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $416.40.

Insider Transactions at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the firm's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares of the company's stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.